3 completed, 1 recruiting, 1 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Olix Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia OLX72021, Placebo - Androgenetic Alopecia (AGA) | Phase 1 / Phase 2 | Recruiting | Olix Pharmaceuticals, Inc. | 158 | 2025-12-04 | 2026-10-13 |
| Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA) - Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Olix Pharmaceuticals, Inc. | 21 | 2023-01-04 | 2025-12-11 |
| Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration Wet Macular Degeneration | Terminated | Johns Hopkins University | 20 | 2021-09-01 | 2022-09-26 | |
| Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery OLX10010 - Hypertrophic Scar | Phase 2 | Completed | Olix Pharmaceuticals, Inc. | 22 | 2021-08-19 | 2024-02-21 |
| A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects OLX10010, Placebo - Cicatrix, Hypertrophic | Phase 1 | Completed | Olix Pharmaceuticals, Inc. | 48 | 2018-05-21 | 2019-08-08 |
Cicatrix, Hypertrophic (2) · Alopecia (1) · Wet Macular Degeneration (1)
United States (3) · Australia (1) · New Zealand (1) · United Kingdom (1)
Alexander Neumeister, MD (1) · Jim Bush, Dr. (1) · Peter A Campochiaro, M.D. (1) · Toni Bransford, MD (1)